Incyte Corp [INCY] stock is trading at $75.59, up 0.93%. An important factor to consider is whether the stock is rising or falling in short-term value. The INCY shares have gain 7.68% over the last week, with a monthly amount glided 10.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Incyte Corp [NASDAQ: INCY] stock has seen the most recent analyst activity on August 01, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $90. Previously, Stifel upgraded its rating to Buy on June 16, 2025, and kept the price target unchanged to $107. On March 18, 2025, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. UBS initiated its recommendation with a Neutral and recommended $77 as its price target on December 17, 2024. BofA Securities upgraded its rating to Buy for this stock on October 29, 2024, and upped its price target to $90. In a note dated October 01, 2024, Wolfe Research initiated an Outperform rating and provided a target price of $84 on this stock.
Incyte Corp [INCY] stock has fluctuated between $53.56 and $83.95 over the past year. Currently, Wall Street analysts expect the stock to reach $75.67 within the next 12 months. Incyte Corp [NASDAQ: INCY] shares were valued at $75.59 at the most recent close of the market. An investor can expect a potential return of 0.11% based on the average INCY price forecast.
Analyzing the INCY fundamentals
Incyte Corp [NASDAQ:INCY] reported sales of 4.58B for the trailing twelve months, which represents a growth of 16.46%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.34 and Total Capital is 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 74.36 points at the first support level, and at 73.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 76.25, and for the 2nd resistance point, it is at 76.92.
Ratios To Look Out For
For context, Incyte Corp’s Current Ratio is 2.85. On the other hand, the Quick Ratio is 2.78. Considering the valuation of this stock, the price to sales ratio is 3.22, the price to book ratio is 3.52 and price to earnings (TTM) ratio is 17.18.
Transactions by insiders
Recent insider trading involved Stein Steven H, EVP & Chief Medical Officer, that happened on Jul 21 ’25 when 3706.0 shares were sold. Officer, STEVEN STEIN completed a deal on Jul 21 ’25 to buy 3706.0 shares. Meanwhile, EVP & General Manager US Flannelly Barry P sold 1340.0 shares on Jul 16 ’25.
